Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Cash (2020 - 2025)

Apellis Pharmaceuticals has reported Change in Cash over the past 6 years, most recently at -$12.8 million for Q4 2025.

  • Quarterly results put Change in Cash at -$12.8 million for Q4 2025, down 189.33% from a year ago — trailing twelve months through Dec 2025 was $55.1 million (down 8.56% YoY), and the annual figure for FY2025 was $55.1 million, down 8.56%.
  • Change in Cash for Q4 2025 was -$12.8 million at Apellis Pharmaceuticals, down from $109.1 million in the prior quarter.
  • Over the last five years, Change in Cash for APLS hit a ceiling of $356.4 million in Q4 2021 and a floor of -$300.1 million in Q1 2021.
  • Median Change in Cash over the past 5 years was -$9.8 million (2022), compared with a mean of -$5.0 million.
  • Peak annual rise in Change in Cash hit 3263.97% in 2023, while the deepest fall reached 706.84% in 2023.
  • Apellis Pharmaceuticals' Change in Cash stood at $356.4 million in 2021, then tumbled by 109.08% to -$32.4 million in 2022, then tumbled by 212.6% to -$101.2 million in 2023, then surged by 114.2% to $14.4 million in 2024, then plummeted by 189.33% to -$12.8 million in 2025.
  • The last three reported values for Change in Cash were -$12.8 million (Q4 2025), $109.1 million (Q3 2025), and $11.6 million (Q2 2025) per Business Quant data.